← All Zhengye Biotechnology Holding LTD filings

Zhengye Biotechnology Holding LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ZYBT
Zhengye Biotechnology Holding LTD
20-F: Zhengye Biotechnology Reports Significant Revenue Decline
Zhengye Biotechnology Holding Limited's Form 20-F filing reveals a substantial revenue decrease in fiscal year 2025, primarily attributed to a downturn in the hog market and strategic sales adjustments.
NASDAQ
ZYBT
Zhengye Biotechnology Holding LTD
20-F: Zhengye Biotechnology Reports Significant Revenue and Profit Decline in 2024 Amidst Strategic Realignment and Persistent China-Related Risks
Zhengye Biotechnology Holding Limited experienced a notable decrease in revenue and net income for the fiscal year ended December 31, 2024, driven by veterinary vaccine market adjustments and a strategic shift to diversify its customer base away from its largest client, while also disclosing material weaknesses in internal financial controls.